ADVFN Logo
Registration Strip Icon for alerts Register for real-time alerts, custom portfolio, and market movers

NAMS NewAmsterdam Pharma Company NV

22.84
0.14 (0.62%)
Last Updated: 14:18:29
Delayed by 15 minutes

Period:

Draw Mode:

Volume 175,606
Bid Price 22.84
Ask Price 22.90
News -
Day High 23.745

Low
5.6326

52 Week Range

High
26.35

Day Low 22.26
Company Name Stock Ticker Symbol Market Type
NewAmsterdam Pharma Company NV NAMS NASDAQ Common Stock
  Price Change Change Percent Stock Price Last Traded
0.14 0.62% 22.84 14:18:29
Open Price Low Price High Price Close Price Prev Close
22.42 22.26 23.745 22.70
Trades Volume VWAP Dollar Volume Avg Volume 52 Week Range
1,511 175,606 $ 23.05 $ 4,046,898 - 5.6326 - 26.35
Last Trade Time Type Quantity Stock Price Currency
14:18:29 100 $ 22.84 USD

NewAmsterdam Pharma Company NV Financials

Market Cap Shares in Issue Float Revenue Profit/Loss EPS PE Ratio
$ 2.04B - - - -2,613.91
Short Interest Dividends Per Share Dividend Yield Ex-Div Date Insider B/S Insider % Owned
- - - -

more financials information »

NewAmsterdam Pharma Comp... News

Loading Messages....

{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}}

Loading Messages....


No posts yet, be the first! No NAMS Message Board. Create One! See More Posts on NAMS Message Board See More Message Board Posts

Historical NAMS Price Data

Period Open High Low VWAP Avg. Daily Vol Change %
1 Week22.2023.74521.76322.57164,1250.642.88%
1 Month24.9924.9920.2922.36168,987-2.15-8.60%
3 Months12.2526.3511.566420.54243,49710.5986.45%
6 Months9.0526.355.632616.56172,14913.79152.38%
1 Year13.5126.355.632614.86128,4469.3369.06%
3 Years11.0032.885.632614.53108,03211.84107.64%
5 Years11.0032.885.632614.53108,03211.84107.64%

NewAmsterdam Pharma Comp... Description

NewAmsterdam Pharma Company N.V., a clinical-stage biopharmaceutical company, develops oral and non-statin medicines for patients at high risk of cardiovascular disease. Its lead product candidate is obicetrapib, a next generation, oral, and low-dose cholesteryl ester transfer protein (CETP) inhibitor, that is in four ongoing Phase 3 and Phase 2b clinical trials as both a monotherapy and a combination therapy with ezetimibe for lowering LDL-C and preventing major adverse cardiovascular events (MACE). NewAmsterdam Pharma Company N.V. is headquartered in Naarden, the Netherlands.

Your Recent History

Delayed Upgrade Clock